Exchange Traded Concepts LLC Lowers Stake in Altimmune, Inc. (NASDAQ:ALT)

Exchange Traded Concepts LLC decreased its position in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 26.4% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 159,573 shares of the company's stock after selling 57,188 shares during the period. Exchange Traded Concepts LLC owned about 0.22% of Altimmune worth $1,151,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in ALT. SG Americas Securities LLC increased its stake in shares of Altimmune by 36.7% during the fourth quarter. SG Americas Securities LLC now owns 47,060 shares of the company's stock valued at $339,000 after buying an additional 12,624 shares during the period. Kraematon Investment Advisors Inc. purchased a new stake in shares of Altimmune in the 4th quarter worth about $222,000. Hennion & Walsh Asset Management Inc. boosted its stake in shares of Altimmune by 18.1% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 205,590 shares of the company's stock valued at $1,482,000 after purchasing an additional 31,482 shares in the last quarter. 180 Wealth Advisors LLC bought a new stake in shares of Altimmune during the 4th quarter valued at about $78,000. Finally, B. Riley Wealth Advisors Inc. raised its stake in Altimmune by 12.9% in the third quarter. B. Riley Wealth Advisors Inc. now owns 23,454 shares of the company's stock worth $144,000 after buying an additional 2,687 shares in the last quarter. 78.05% of the stock is owned by hedge funds and other institutional investors.

Altimmune Stock Down 1.0 %

Shares of NASDAQ ALT traded down $0.07 during trading on Tuesday, reaching $6.93. The company had a trading volume of 1,466,236 shares, compared to its average volume of 2,264,879. Altimmune, Inc. has a 12-month low of $5.28 and a 12-month high of $14.84. The business's 50-day moving average is $7.87 and its 200 day moving average is $7.19. The stock has a market cap of $492.86 million, a PE ratio of -4.47 and a beta of 0.22.

Altimmune (NASDAQ:ALT - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.03. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The business had revenue of $0.01 million for the quarter. During the same period last year, the company posted ($0.39) earnings per share. On average, analysts anticipate that Altimmune, Inc. will post -1.35 earnings per share for the current year.

Analyst Upgrades and Downgrades

ALT has been the topic of several research reports. HC Wainwright reaffirmed a "buy" rating and set a $12.00 price objective on shares of Altimmune in a research report on Wednesday, January 22nd. Stifel Nicolaus began coverage on Altimmune in a research note on Wednesday, January 8th. They issued a "buy" rating and a $18.00 price target on the stock. Finally, UBS Group initiated coverage on Altimmune in a research report on Tuesday, November 12th. They set a "buy" rating and a $26.00 price objective for the company. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Altimmune currently has a consensus rating of "Buy" and an average target price of $20.83.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.